• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Sources of regulatory information for pharmacists.

作者信息

Goldwire M A, Rumore M M

机构信息

International Drug Information Center, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, NY 11201.

出版信息

Am J Hosp Pharm. 1993 Jun;50(6):1175-81.

PMID:8517457
Abstract

Sources of regulatory information of use to pharmacists are summarized. Regulatory information is provided by government, legal, pharmaceutical industry, nongovernment, and investigational drug sources. Databases and trade and professional organizations also provide such information. Information on legislative statutes and regulations can be found in the Federal Register, Code of Federal Regulations, and List of CFR Sections Affected. Many other government reports are also available. Various law reports are published by state and federal courts; legal textbooks, journals, and newsletters also provide pharmacy law information. Pharmaceutical industry sources supply information on U.S. drug approvals, pharmaceutical companies, and FDA enforcement actions, whereas nongovernment regulatory sources provide comprehensive regulatory and drug information. Investigational drug sources enable pharmacists to keep abreast of new drug development. Databases provide a wide variety of information, and trade newsletters supply information of interest to the organization. Knowledge of appropriate references will allow pharmacists to keep abreast of regulations that may affect them and new developments in their area of expertise.

摘要

相似文献

1
Sources of regulatory information for pharmacists.
Am J Hosp Pharm. 1993 Jun;50(6):1175-81.
2
Investigational drug tracking: Phases I-III and NDA submissions--Part I.研究性药物追踪:I至III期及新药申请提交——第一部分
Hosp Pharm. 1994 Sep;29(9):830-6, 839-44, 847-52 passim.
3
[An analysis of the pharmaceuticals market in Vietnam].[越南药品市场分析]
Sante. 2001 Jul-Sep;11(3):155-60.
4
Investigational drug tracking: phases I-III and NDA submissions--Part II.研究性药物追踪:I-III期及新药申请提交——第二部分。
Hosp Pharm. 1994 Oct;29(10):900, 902-4, 906-11 passim.
5
Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.现行药品生产质量管理规范及用于临床试验的研究性新药。最终规定。
Fed Regist. 2008 Jul 15;73(136):40453-63.
6
Regulatory aspects of investigational new drugs.新药研究的监管方面。
Am J Hosp Pharm. 1978 Jan;35(1):81-5.
7
[Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].[制药公司与全球监管机构在整个研发阶段的接触与对话]
Ugeskr Laeger. 2003 Apr 14;165(16):1649-52.
8
Economics of new oncology drug development.新型肿瘤药物研发的经济学
J Clin Oncol. 2007 Jan 10;25(2):209-16. doi: 10.1200/JCO.2006.09.0803.
9
Physician dispensing: issues of law, legislation and social policy.医生配药:法律、立法及社会政策问题。
Am J Law Med. 1989;14(4):307-52.
10
Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.埃塞俄比亚的药品监管框架:对其法律基础与实施情况的批判性评估
Ethiop J Health Sci. 2016 May;26(3):259-76. doi: 10.4314/ejhs.v26i3.9.